Ligand Appoints Pharmaceutical Executive Sarah Boyce to its Board of Directors
SAN DIEGO–(BUSINESS WIRE)–Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) (“Ligand” or “the Company”) announces the appointment of Sarah Boyce to the Company’s…
Pharmaceuticals, Biotechnology and Life Sciences
SAN DIEGO–(BUSINESS WIRE)–Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) (“Ligand” or “the Company”) announces the appointment of Sarah Boyce to the Company’s…
Checkmate Pharmaceuticals has added experienced industry executives to lead clinical research and regulatory affairs with the appointments of James Wooldridge,…
SAN DIEGO–(BUSINESS WIRE)–BioMed Realty, a leading provider of real estate solutions for the life science industry, announced today that it…
Allergan’s shareholders have voted to approve to be bought by AbbVie Inc for approximately $63 billion, as more than 99 percent of the votes cast were in favor of the transaction, representing about 69% of the shares outstanding and eligible to be voted at each of the Allergan shareholder meetings held on October 14, 2019 in Dublin, Ireland.
The U.S. Food and Drug Administration (FDA) has approved Xarelto (rivaroxaban) for the prevention of venous thromboembolism (VTE), or blood clots, in hospitalized acutely ill medical patients at risk for thromboembolic complications who are not at high risk of bleeding, Janssen said Monday in a press release.
Lineage Cell Therapeutic has presented results of testing OpRegen, which continues to be well tolerated with increased visual acuity observed…
LAGUNA HILLS, Calif.–(BUSINESS WIRE)–#INDstatus—PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes…
Anika Therapeutics welcomes as new Vice President of regulatory affairs an industry veteran who brings extensive experience leading global regulatory,…
SAN DIEGO, Calif.–(BUSINESS WIRE)–Abzena announced today the appointment of Kimball Hall as Chief Operating Officer, adding to the company’s executive…
Pfizer has presented positive phase 3 data at the 28th Congress of the European Academy of Dermatology and Venereology for abrocitinib in moderate to severe atopic dermatitis, in which abrocitinib met all co-primary and secondary endpoints in JADE MONO-1 study.